4.4 Review Book Chapter

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Journal

DIABETES THERAPY
Volume 5, Issue 2, Pages 355-366

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s13300-014-0089-4

Keywords

Anti-diabetic drugs; Cardiovascular safety; Canagliflozin; Dapagliflozin; Empagliflozin; Perineal hygiene; Sodium-glucose co-transporter-2 inhibitors

Ask authors/readers for more resources

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available